Tags

Type your tag names separated by a space and hit enter

Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism.
Fertil Steril. 2003 Apr; 79(4):942-6.FS

Abstract

OBJECTIVE

To compare the effectiveness of cyproterone acetate, finasteride, and spironolactone in the treatment of idiopathic hirsutism.

DESIGN

Prospective randomized clinical study.

SETTING

University hospital.

PATIENT(S)

Forty-one women (median age, 21 years [range, 18-34 years]) with idiopathic hirsutism who had requested to use an oral contraceptive.

INTERVENTION(S)

Patients were randomly assigned to receive cyproterone acetate (12.5 mg/d for the first 10 days of the cycle), finasteride (5 mg/d), or spironolactone (100 mg/d) for 12 months. Follow-up was done at the end of therapy.

MAIN OUTCOME MEASURE(S)

Ferriman-Gallwey score before treatment, at 6 and 12 months of treatment, and 1 year after the end of treatment, and androgenic profile before and after treatment.

RESULT(S)

At the end of therapy, the Ferriman-Gallwey score decreased by 38.9%, 38.6%, and 38.5% in patients who used cyproterone acetate, finasteride, and spironolactone, respectively. One year after therapy, the Ferriman-Gallwey score of patients who used spironolactone was significantly lower (6.74 +/- 1.41) than that of patients who used either cyproterone acetate (7.92 +/- 1.08), or finasteride (9.08 +/- 0.99). The androgenic profile did not change significantly during treatment.

CONCLUSION(S)

In patients with idiopathic hirsutism, the short-term results of treatment with cyproterone acetate, finasteride, and spironolactone are similar, but spironolactone is effective for a longer time.

Authors+Show Affiliations

Lumachi F
Department of Surgical and Gastroenterological Sciences, University of Padua, School of Medicine, Padova, Italy. flumachi@unipd.it
Rondinone R
No affiliation info available

MeSH

17-alpha-HydroxyprogesteroneAdolescentAdultAndrogen AntagonistsAndrostenedioneCyproterone AcetateDehydroepiandrosterone SulfateEnzyme InhibitorsFemaleFinasterideHirsutismHumansProspective StudiesSpironolactoneTestosterone

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

12749435

Citation

Lumachi, Franco, and Riccardo Rondinone. "Use of Cyproterone Acetate, Finasteride, and Spironolactone to Treat Idiopathic Hirsutism." Fertility and Sterility, vol. 79, no. 4, 2003, pp. 942-6.
Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril. 2003;79(4):942-6.
Lumachi, F., & Rondinone, R. (2003). Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertility and Sterility, 79(4), 942-6.
Lumachi F, Rondinone R. Use of Cyproterone Acetate, Finasteride, and Spironolactone to Treat Idiopathic Hirsutism. Fertil Steril. 2003;79(4):942-6. PubMed PMID: 12749435.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. AU - Lumachi,Franco, AU - Rondinone,Riccardo, PY - 2003/5/17/pubmed PY - 2003/6/6/medline PY - 2003/5/17/entrez SP - 942 EP - 6 JF - Fertility and sterility JO - Fertil Steril VL - 79 IS - 4 N2 - OBJECTIVE: To compare the effectiveness of cyproterone acetate, finasteride, and spironolactone in the treatment of idiopathic hirsutism. DESIGN: Prospective randomized clinical study. SETTING: University hospital. PATIENT(S): Forty-one women (median age, 21 years [range, 18-34 years]) with idiopathic hirsutism who had requested to use an oral contraceptive. INTERVENTION(S): Patients were randomly assigned to receive cyproterone acetate (12.5 mg/d for the first 10 days of the cycle), finasteride (5 mg/d), or spironolactone (100 mg/d) for 12 months. Follow-up was done at the end of therapy. MAIN OUTCOME MEASURE(S): Ferriman-Gallwey score before treatment, at 6 and 12 months of treatment, and 1 year after the end of treatment, and androgenic profile before and after treatment. RESULT(S): At the end of therapy, the Ferriman-Gallwey score decreased by 38.9%, 38.6%, and 38.5% in patients who used cyproterone acetate, finasteride, and spironolactone, respectively. One year after therapy, the Ferriman-Gallwey score of patients who used spironolactone was significantly lower (6.74 +/- 1.41) than that of patients who used either cyproterone acetate (7.92 +/- 1.08), or finasteride (9.08 +/- 0.99). The androgenic profile did not change significantly during treatment. CONCLUSION(S): In patients with idiopathic hirsutism, the short-term results of treatment with cyproterone acetate, finasteride, and spironolactone are similar, but spironolactone is effective for a longer time. SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/12749435/Use_of_cyproterone_acetate_finasteride_and_spironolactone_to_treat_idiopathic_hirsutism_ DB - PRIME DP - Unbound Medicine ER -